OptiBiotix Health PLC Commercial Appointments
01 Março 2022 - 4:01AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
01 March 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company ")
Commercial Appointments
OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, high cholesterol, blood
pressure, diabetes, ann o un ces the following appointments(1) :
Zac Sniderman as Business Development & Sales Director North
America, Shiraz Butt as E-Commerce Director and Karl Burkitt as
Marketing Director.
Zac brings a broad experience developing a food and supplement
ingredient businesses in North America working for Galenicum
Speciality Ingredients, Jarrow Formulas and Best Ground
International. He has an entrepreneurial mindset and an extensive
network. He will focus on the development of ingredient sales to
brand owners and contract manufacturers for both pro- and
prebiotics in close cooperation with our established partners.
Shiraz has successfully developed the e-commerce businesses for
a range of companies, such as PhD (now part of Science In Sports)
and Iovate Health Sciences. He has built digital sales from the
ground up into significant contributors to the success of the
companies he has worked for. Shiraz will focus on developing the
untapped e-commerce potential of our pro- and prebiotic brands such
as SlimBiome Medical, Go-Figure and CholBiome.
Karl Burkitt has a rich career in which he developed and led the
marketing and business development function in various branded and
ingredient businesses, such as Novartis Consumer Health, Kerry
Ingredients & Flavours and AB Mauri. Karl will lead our
marketing function, on a part time basis, and work closely with the
pro- and prebiotic commercial divisions on developing ingredient
and consumer sales.
The above appointments expand the capabilities of our management
team in line with our commercial strategy , which is to further
expand ingredient sales, particularly in the large North American
market, whilst developing our final product sales containing our
unique ingredients.
René Kamminga, CEO of OptiBiotix Ltd, commented: "In the past 12
months we have established the credibility and brand awareness of
our science - based ingredients SlimBiome(R), OptiBiome, LeanBiome
and LP(LDL) (R) ingredients, significantly growing sales to a wider
number of reputable global brands in multiple markets. These
appointments are a further investment to accelerate the growth of
the Company and to broaden and deepen our income streams with a
particular focus on North America and E-Commerce ."
(1) These appointments are non-statutory director appointments
in the Company or its subsidiaries.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07407 804 654
Alice Woodings
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRATPMRTMTJTBAT
(END) Dow Jones Newswires
March 01, 2022 02:01 ET (07:01 GMT)
Optibiotix Health (LSE:OPTI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024